Aptivus (Tipranavir)

See also: Medication Side Effects | Drug Interactions | All HIV Medications

Brand Name:	Aptivus
Generic Name:	Tipranavir
Adult Single Dose:	Two 250-mg softgels, taken with two 100-mg capsules of ritonavir (twice a day)
Food & Liquid Restrictions:	Take with food
Drug Class:	PI

From The Body's "Ask the Experts" Forums

» More questions

The Basics

An Overview of Aptivus (Tipranavir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
FAQs About Tipranavir (Aptivus) From The Body's "Ask the Experts" Forums (Regularly Updated)
From The Body's "Ask the Experts" Forums
Tipranavir Patient Assistance Program (Regularly Updated)
Can't afford this medication? Click the link above to see if you qualify for the patient assistance program or call 1-800-556-8317.
From RxHope
Aptivus (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Tipranavir (Aptivus) (June 26, 2008)
To read PDF, click here
From AIDS InfoNet
Patient Information About Aptivus (Tipranavir) (PDF) (June 2008)
From Boehringer Ingelheim
Aptivus (Tipranavir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Tipranavir: The First Nonpeptidic Protease Inhibitor (Winter 2003/2004)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Aptivus (Tipranavir): An In-Depth Look (Spring 2006)
Includes background information, study results, potential uses and side effects.
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America

News

New Pediatric Dosing for Aptivus, Patients 2-18 Years, New Oral Solution and Info on Coadministration With Midazolam (June 23, 2008)
From U.S. Food and Drug Administration

Research

New Data on Tipranavir Highlight the Agent's Benefits (July 25, 2007)
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
A Research Update on Tipranavir (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
A Thorough Look at Tipranavir Based on Studies Assessing Its Efficacy, Resistance and Safety (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
Tipranavir/Ritonavir-Associated Hepatotoxicity Common, But Resolves Over Time (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Virologic Outcomes With Tipranavir + Ritonavir Prove to Be Durable Out to 96 Weeks in the RESIST Studies (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Whereas Other PIs Fail, Tipranavir Maintains High-Level Potency Against Key PI Resistance Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Ritonavir-Boosted Tipranavir More Effective Than Other Ritonavir-Boosted PIs in HIV-Infected Patients With PI Resistance (August 17, 2006)
In XVI International AIDS Conference
Use of Tipranavir for Patients With Little Prior PI Experience (August 15, 2006)
In XVI International AIDS Conference
Tipranavir Update at CROI 2006: RESIST Study Results, Drug Interactions and Therapeutic Drug Monitoring (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
Study of Tipranavir for First-Line Treatment Ends Early (June 9, 2006)
Newly released results from an industry-sponsored study make it doubtful that tipranavir will ever be used as first-line therapy.
From Boehringer Ingelheim